Although ABL1-specific tyrosine kinase inhibitors (TKIs) including nilotinib have dramatically improved the prognosis of patients with CML, the TKI efficacy depends on the individual patient. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.